Tanvex BioPharma Company Description

Tanvex BioPharma, Inc., a biopharmaceutical company, researches, develops, manufactures, and sells biosimilar products in Taiwan and the United States.

It focuses on delivering biosimilars which target neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis.

The company’s products pipeline includes TX01 and TX-05 which have completed Phase III clinical trials; TX-04 and TX-16 that are in Phase I clinical trial; and TX-52 and other products which are in pre-clinical trial.

The company was formerly known as Ruenvex Biotech, Inc. Tanvex BioPharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.

Tanvex BioPharma, Inc.

Country	Cayman Islands
Founded	2013
Industry	Biotechnology
Sector	Healthcare
Employees	149
CEO	Stephen Lam

Contact Details

Address: 802 West Bay Road George Town, KY1-1205 Cayman Islands
Website	tanvex.com

Stock Details

Ticker Symbol	6541
Exchange	Taiwan Exchange
Fiscal Year	January - December
Reporting Currency	TWD
ISIN Number	KYG8676P1037
SIC Code	2836

Key Executives

Name	Position
Stephen Lam	Chief Executive Officer
Dr. Lin-Cheng Chen J.D.	Chairman and Chief Executive Officer
Dr. Allen Y. Chao Ph.D.	Founder and Honorary Chairman
Wen Chung Yeh	Chief Financial Officer
Val Chen	Vice President of Finance Director of Ops. Mgmt., Corporate Governance Officer and Chief Internal Auditor
James Williamson	Accounting Officer
Zheng Xia	Chief Technology Officer
Linda Grillo	Director of Sales and Marketing
Hsun-Chiang Hsieh	Secretary